A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

262

Participants

Timeline

Start Date

September 20, 2023

Primary Completion Date

December 11, 2024

Study Completion Date

April 9, 2025

Conditions
Atopic Dermatitis
Interventions
DRUG

LEO 138559

LEO 138559 given by injection just under the skin

DRUG

Placebo

Placebo given by injection just under the skin

Trial Locations (73)

4032

LEO Investigational Site, Debrecen

6720

LEO Investigational Site, Szeged

7632

LEO Investigational Site, Pécs

10029

LEO Investigational Site, New York

10117

LEO Investigational Site, Berlin

13500

LEO Investigational Site, Martigues

14004

LEO Investigational Site, Córdoba

15831

LEO Investigational Site, Mahlow

21000

LEO Investigational Site, Dijon

24105

LEO Investigational Site, Kiel

27609

LEO Investigational Site, Raleigh

28046

LEO Investigational Site, Madrid

29420

LEO Investigational Site, North Charleston

33012

LEO Investigational Site, Hialeah

44124

LEO Investigational Site, Mayfield Heights

45219

LEO Investigational Site, Cincinnati

46250

LEO investigational site, Indianapolis

47150

LEO investigational Site, New Albany

48103

LEO Investigational Site, Ann Arbor

48149

LEO Investigational Site, Münster

48455

LEO Investigational Site, Bad Bentheim

50009

LEO Investigational Site, Zaragoza

60590

LEO Investigational Site, Frankfurt am Main

75010

LEO Investigational Site, Paris

76031

LEO Investigational Site, Rouen

79104

LEO Investigational Site, Freiburg im Breisgau

86179

LEO Investigational Site, Augsburg

90045

LEO Investigational Site, Los Angeles

92708

LEO Investigational Site, Fountain Valley

94115

LEO Investigational Site, San Francisco

300757

LEO Investigational Site, Timișoara

400152

LEO Investigational Site, Cluj-Napoca

700291

LEO Investigational Site, Iași

T5J 3S9

LEO Investigational Site, Edmonton

T2J 7E1

LEO Investigational Site, Calgary

T2W 4X9

LEO Investigational Site, Calgary

T6G 1C3

LEO Investigational Site, Edmonton

V3R 6A7

LEO Investigational Site, Surrey

L4Y 4C5

LEO Investigational Site, Mississauga

J1G 1X9

LEO Investigational Site, Sherbrooke

H4G 3E7

LEO Investigational Site, Verdun

547 01

LEO Investigational Site, Náchod

708 52

LEO Investigatonal Site, Ostrava-Poruba

100 34

LEO Investigational Site, Prague

150 00

LEO Investigational Site, Prague

06000

LEO Investigational Site, Nice

01307

LEO Investigational Site, Dresden

07548

LEO Investigational Site, Gera

04103

LEO Investigational Site, Leipzig

815-8588

LEO Investigational Site, Fukuoka

657-0846

LEO Investigational Site, Kobe

220-6208

LEO Investigational Site, Yokohama

231-0801

LEO Investigational Site, Yokohama

569-0824

LEO Investigational Site, Takatsuki-shi

136-0074

LEO Investigational Site, Koto-ku

933-0871

LEO Investigational Site, Takaoka-shi

167-0051

LEO Investigational Site, Tokyo

50-450

LEO Investigational Site, Wroclaw

30-033

LEO Investigational Site, Krakow

31-011

LEO Investigational Site, Krakow

82-200

LEO Investigational Site, Malbork

43-190

LEO Investigational Site, Mikołów

50-224

LEO Investigational Site, Wroclaw

08915

LEO Investigational Site, Badalona

5-28100

LEO Investigational Site, Alcobendas

03010

LEO Investigational Site, Alicante

08907

LEO Investigational Site, Barcelona

EH16 4SA

LEO Investigational Site, Edinburgh

HA1 3UJ

LEO Investigational Site, Harrow

E1 1FR

LEO Investigational Site, London

M23 9QZ

LEO Investigational Site, Manchester

SO16 6YD

LEO Investigational Site, Southampton

WS2 9PS

LEO Investigational Site, Walsall

Sponsors

Lead Sponsor

All Listed Sponsors
lead

LEO Pharma

INDUSTRY